160 related articles for article (PubMed ID: 35617682)
1. Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease.
Kim HT; Koreth J; Whangbo J; Nikiforow S; Reynolds CG; Stowe P; Ho VT; Cutler C; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2022 Aug; 6(15):4392-4402. PubMed ID: 35617682
[TBL] [Abstract][Full Text] [Related]
2. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
Front Immunol; 2022; 13():954966. PubMed ID: 36189229
[TBL] [Abstract][Full Text] [Related]
3. A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease.
Whangbo JS; Nikiforow S; Kim HT; Wahl J; Reynolds CG; Rai SC; Kim S; Burden A; Alho AC; Lacerda JF; Alyea EP; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2022 Nov; 6(21):5786-5796. PubMed ID: 35475885
[TBL] [Abstract][Full Text] [Related]
4. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.
Koreth J; Kim HT; Jones KT; Lange PB; Reynolds CG; Chammas MJ; Dusenbury K; Whangbo J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Chen YB; Avigan D; Blazar BR; Antin JH; Ritz J; Soiffer RJ
Blood; 2016 Jul; 128(1):130-7. PubMed ID: 27073224
[TBL] [Abstract][Full Text] [Related]
5. Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease.
Whangbo JS; Kim HT; Nikiforow S; Koreth J; Alho AC; Falahee B; Kim S; Dusenbury K; Fields MJ; Reynolds CG; Alyea EP; Armand P; Cutler CS; Ho VT; Antin JH; Soiffer RJ; Ritz J
Blood Adv; 2019 Apr; 3(7):984-994. PubMed ID: 30936059
[TBL] [Abstract][Full Text] [Related]
6. Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo JS; Kim HT; Mirkovic N; Leonard L; Poryanda S; Silverstein S; Kim S; Reynolds CG; Rai SC; Verrill K; Lee MA; Margossian S; Duncan C; Lehmann L; Huang J; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Soiffer RJ; Ritz J; Koreth J
Blood Adv; 2019 Sep; 3(17):2550-2561. PubMed ID: 31471324
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.
Belizaire R; Kim HT; Poryanda SJ; Mirkovic NV; Hipolito E; Savage WJ; Reynolds CG; Fields MJ; Whangbo J; Kubo T; Nikiforow S; Alyea EP; Armand P; Cutler CS; Ho VT; Blazar BR; Antin JH; Ritz J; Soiffer RJ; Koreth J
Blood Adv; 2019 Apr; 3(7):969-979. PubMed ID: 30936057
[TBL] [Abstract][Full Text] [Related]
8. Real-world experience with low-dose IL-2 for children and young adults with refractory chronic graft-versus-host disease.
Wobma H; Kapadia M; Kim HT; Alvarez-Calderon F; Baumeister SHC; Duncan C; Forrest S; Gorfinkel L; Huang J; Lehmann LE; Li H; Schwartz M; Koreth J; Ritz J; Kean LS; Whangbo JS
Blood Adv; 2023 Aug; 7(16):4647-4657. PubMed ID: 37603347
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T Cells in Chronic Graft-Versus-Host Disease After Extracorporeal Photopheresis: Correlation With Skin and Global Organ Responses, and Ability to Taper Steroids.
Denney HA; Whittle RJ; Lai J; Jacques RM; Taylor PC
Transplantation; 2017 Jan; 101(1):204-211. PubMed ID: 27007227
[TBL] [Abstract][Full Text] [Related]
10. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD.
Alho AC; Kim HT; Chammas MJ; Reynolds CG; Matos TR; Forcade E; Whangbo J; Nikiforow S; Cutler CS; Koreth J; Ho VT; Armand P; Antin JH; Alyea EP; Lacerda JF; Soiffer RJ; Ritz J
Blood; 2016 Feb; 127(5):646-57. PubMed ID: 26670634
[TBL] [Abstract][Full Text] [Related]
11. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
Front Immunol; 2021; 12():673636. PubMed ID: 34276662
[TBL] [Abstract][Full Text] [Related]
12. A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease.
Curtis LM; Ostojic A; Venzon DJ; Holtzman NG; Pirsl F; Kuzmina ZJ; Baird K; Rose JJ; Cowen EW; Mays JW; Mitchell SA; Parsons-Wandell L; Joe GO; Comis LE; Berger A; Pusic I; Peer CJ; Figg WD; Cao L; Gale RP; Hakim FT; Pavletic SZ
Blood; 2021 Feb; 137(7):896-907. PubMed ID: 32976576
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of ruxolitinib in steroid-refractory graft-versus-host disease: A meta-analysis.
Fan S; Huo WX; Yang Y; Shen MZ; Mo XD
Front Immunol; 2022; 13():954268. PubMed ID: 35990629
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Ruxolitinib for Steroid-Refractory Chronic Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation.
Wu H; Shi J; Luo Y; Tan Y; Zhang M; Lai X; Yu J; Liu L; Fu H; Huang H; Zhao Y
JAMA Netw Open; 2021 Jan; 4(1):e2034750. PubMed ID: 33502484
[TBL] [Abstract][Full Text] [Related]
15. An Open-Label, Single-Arm, Multicenter Study of Ibrutinib in Japanese Patients With Steroid-dependent/Refractory Chronic Graft-Versus-Host Disease.
Doki N; Toyosaki M; Shiratori S; Osumi T; Okada M; Kawakita T; Sawa M; Ishikawa T; Ueda Y; Yoshinari N; Nakahara S
Transplant Cell Ther; 2021 Oct; 27(10):867.e1-867.e9. PubMed ID: 34102349
[TBL] [Abstract][Full Text] [Related]
16. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
Front Immunol; 2021; 12():749266. PubMed ID: 34621279
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience.
Chin KK; Kim HT; Inyang EA; Ho V; Koreth J; Romee R; Gooptu M; Shapiro R; Antin J; Soiffer R; Jaglowski S; Pidala J; Cutler C
Transplant Cell Ther; 2021 Dec; 27(12):990.e1-990.e7. PubMed ID: 34481113
[TBL] [Abstract][Full Text] [Related]
18. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
Yamashita K; Horwitz ME; Kwatemaa A; Nomicos E; Castro K; Sokolic R; Foster SF; Garofalo M; Choi U; Ryherd M; Brown MR; Leitman SF; Wayne AS; Fowler DH; Bishop MR; Childs RW; Barrett AJ; Pavletic SZ; Malech HL
Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):22-30. PubMed ID: 16399598
[TBL] [Abstract][Full Text] [Related]
19. Efficiency and Toxicity of Imatinib Mesylate combined with Atorvastatin Calcium in the Treatment of Steroid-Refractory Chronic Graft-Versus-Host Disease: A Single-center, Prospective, Single-arm, Open-label study.
Chen T; Li J; Wei X; Yao H; Zhu L; Liu J; Liu Y; Wang P; Feng Y; Gao S; Liu H; Wang L; Zhao L; Gao L; Zhang C; Gao L; Zhang X; Kong P
Acta Haematol; 2024 Jan; ():. PubMed ID: 38232716
[TBL] [Abstract][Full Text] [Related]
20. Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD.
Baek DW; Cho HJ; Kim JH; Ahn JS; Kim HJ; Lim SN; Cheong JW; Kim SY; Lee HS; Won JH; Yhim HY; Sohn SK; Moon JH
Cell Transplant; 2022; 31():9636897221113789. PubMed ID: 35861214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
